Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Blood Cancer J. 2012 Mar;2(3):e59. doi: 10.1038/bcj.2012.3. Epub 2012 Mar 2.

How to manage the transplant question in myelofibrosis.

Author information

  • Division of Hematology/Oncology, Massachusetts General Hospital , Boston, MA, USA.

Abstract

Allogeneic stem cell transplantation remains the only curative therapy for myelofibrosis. Despite advances in transplant, the morbidity and the mortality of the procedure necessitate careful patient selection. In this manuscript, we describe the new prognostic scoring system to help select appropriate patients for transplant and less aggressive therapies. We explore the advances in non-transplant therapy, such as with investigational agents. We review the blossoming literature on results of myeloablative, reduced intensity and alternative donor transplantation. Finally, we make recommendations for which patients are most likely to benefit from transplantation.

PMID:
22829254
[PubMed]
PMCID:
PMC3317522
Free PMC Article

Images from this publication.See all images (1)Free text

Figure 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk